Kara Cain, APRN
Nurse Practitioner · Myrtle Beach, SCNPI 1548726482
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 780 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AbbVie at 32.2% of the total. Among nurse practitioner clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 780 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Johnson & Johnson$1K
- Takeda Pharmaceuticals U.S.A., Inc.$902
- Phathom Pharmaceuticals, Inc.$761
- Gilead$654
- plus $5K from 28 others
What the payments were for
- Food & beverage$14,566100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 237 | $4,690 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 95 | $1,336 |
| Johnson & Johnson | 84 | $1,242 |
| Takeda Pharmaceuticals U.S.A., Inc. | 46 | $902 |
| Phathom Pharmaceuticals, Inc. | 24 | $761 |
| Gilead | 31 | $654 |
| Ardelyx, Inc. | 31 | $479 |
| Sanofi | 17 | $449 |
| QOL Medical, LLC | 26 | $445 |
| Ironwood Pharmaceuticals, Inc | 23 | $378 |
| Pfizer | 21 | $378 |
| Lilly USA, LLC | 21 | $369 |
| Daiichi Sankyo Inc. | 17 | $343 |
| Nestle Healthcare Nutrition Inc. | 15 | $313 |
| Bristol Myers Squibb | 15 | $214 |
| Intercept Pharmaceuticals, Inc. | 13 | $204 |
| Medtronic | 2 | $194 |
| Madrigal Pharmaceuticals | 11 | $176 |
| Aimmune Therapeutics, Inc. | 6 | $120 |
| Regeneron Healthcare Solutions, Inc. | 5 | $118 |
| Ferring Pharmaceuticals Inc. | 8 | $115 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $104 |
| Ipsen Biopharmaceuticals, Inc | 5 | $101 |
| Redhill Biopharma Inc. | 5 | $81 |
| Merck | 5 | $71 |
| Alnylam Pharmaceuticals Inc. | 3 | $70 |
| Mallinckrodt Hospital Products Inc. | 3 | $63 |
| Novo Nordisk | 3 | $62 |
| Intra-sana Laboratories | 2 | $35 |
| Revance Therapeutics, Inc. | 1 | $33 |
| Janssen Scientific Affairs, LLC | 1 | $25 |
| Enterra Medical, Inc. | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Axonics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,584 in reported general payments places this provider in the 95th percentile of 1,346 nurse practitioner providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 27 | $165,369 |
| CreonLipase/Protease/Amylase | 23 | $98,115 |
| LinzessLinaclotide | 44 | $56,832 |
| XifaxanRifaximin | 18 | $45,636 |
| MotegrityPrucalopride Succinate | 19 | $21,861 |
| Lubiprostone | 21 | $5,101 |
| Esomeprazole Magnesium | 35 | $4,513 |
| Pantoprazole Sodium | 254 | $4,099 |
| Omeprazole | 259 | $3,704 |
| Cholestyramine LightCholestyramine | 41 | $3,494 |
| Famotidine | 178 | $3,203 |
| Mesalamine | 14 | $3,157 |
| Dicyclomine Hcl | 100 | $2,210 |
| Colestipol Hcl | 14 | $1,065 |
| Sucralfate | 29 | $456 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aimmune Therapeutics, Inc.Zenpep | $120 | $165,36927 claims |
| AbbVieCreon, Linzess | $4,690 | $154,94767 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,336 | $45,63618 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $902 | $21,86119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,346 nurse practitioner providers in South Carolina.
Other nurse practitioner in Myrtle Beach
- Alissa StrojnyMyrtle Beach$18K
- Natali AmaradasaMyrtle Beach$15K
- Amanda RobertsonMyrtle Beach$9K
- David WiltGreenville$90K
- Whitney ReedCharleston$54K
- Mary JohnsonCharleston$34K
- Amanda HareCharleston$30K
- Kellie McLainCharleston$28K
- Colleen BoydSummerville$21K
- Mae BurtonGreenville$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.